

: LJI308 **Product Name**

: LJI308; LJI-308; LJI 308; NVP-LJI308; NVP-LJI-308 **Synonyms**

Cat No. : M17345

CAS Number 1627709-94-7

Molecular Formula : C21H18F2N2O2

: 368.38 Formula Weight

Chemical Name : 2,6-Difluoro-4-[4-[4-(4-morpholinyl)phenyl]-3-pyridinyl]-phenol

LJI308 is a RSK inhibitor. LJI308 overcomes chemoresistance by eliminating cancer stem cells. LJI308 targets the CSC population and repress TNBC growth and dissemination. LJI308 specifically targeted transformed cells as it had little effect

on the non-tumorigenic parental HMECs. Targeting RSK using specific and potent inhibitors, such as LJI308, delivers the

promise of inhibiting the growth of TNBC.

Pathway : Angiogenesis

: PDE **Target**

Description

Receptor : RSK1;RSK2;RSK3

Solubility : DMSO : ≥ 32 mg/mL 86.87 mM

SMILES Oc1c(F)cc(cc1F)-c1cnccc1-c1ccc(cc1)N1CCOCC1

: (-20℃) Storage

Stability : ≥2 years

Reference

1. Aronchik I, Appleton B A, Basham S E, et al. Molecular Cancer Research, 2014, 12(5): 803-812.